Filtered By:
Cancer: Bone Cancers

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 366 results found since Jan 2013.

ZBTB7C m6A modification incurred by METTL3 aberration promotes osteosarcoma progression
Transl Res. 2023 Apr 28:S1931-5244(23)00072-5. doi: 10.1016/j.trsl.2023.04.005. Online ahead of print.ABSTRACTAberrant N6-methyladenosine (m6A) modification of mRNAs contributes significantly to the epigenetic tumorigenesis, however, its precise role and the key targets in osteosarcoma (OS) are not defined. Here we reported that selective METTL3 (methyltransferase like 3) elevation and the consequential increase of m6A modification causally affect OS progression. The fast-growing OS cells displayed preferential upregulation of METTL3 and increased m6A modification. Conversely, m6A inhibition by 3-deazaadenosine, siRNA-medi...
Source: Translational Research : the journal of laboratory and clinical medicine - April 30, 2023 Category: Laboratory Medicine Authors: Xueying An Wenshu Wu Lin Yang Jian Dong Bin Liu Junxia Guo Jianmei Chen Baosheng Guo Wangsen Cao Qing Jiang Source Type: research

Co-delivery of curcumin and si-STAT3 with a bioinspired tumor homing for polydopamine nanoparticles for synergistic osteosarcoma therapy
ConclusionThis study revealed that CPDA/siSTAT3@SCM NPs can target drug delivery by biomimetic multifunctional nanoparticles to treat OS through chemo-gene combined therapy.
Source: Cancer Nanotechnology - June 20, 2023 Category: Cancer & Oncology Source Type: research

Interleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcoma.
Abstract Osteosarcoma is characterized by a high malignant and metastatic potential. Angiogenesis is essential for the caner metastasis. Interleukin-6 (IL-6) is a multifunctional cytokine that is associated with the disease status and outcomes of cancers. However, the relationship between IL-6 and vascular endothelial growth factor (VEGF) expression in human osteosarcoma is mostly unknown. Here we found that the IL-6 and VEGF expression was correlated with tumor stage and significantly higher than that in normal bone. Incubation of osteosarcoma cells with IL-6 increased VEGF mRNA and protein expression. Pretreatme...
Source: Biochemical Pharmacology - December 5, 2012 Category: Drugs & Pharmacology Authors: Tzeng HE, Tsai CH, Chang ZL, Su CM, Wang SW, Hwang WL, Tang CH Tags: Biochem Pharmacol Source Type: research

Heat shock protein expression analysis in canine osteosarcoma reveals HSP60 as a potentially relevant therapeutic target.
This study was performed to assess the prognostic and predictive values of the gene expression of HSP family members in canine osteosarcoma (OS) and their potential for targeted therapy. Gene expressions for HSP were assessed using quantitative PCR (qPCR) on 58 snap-frozen primary canine OS tumors and related to clinic-pathological parameters. A significant increased expression of HSP60 was found in relation to shorter overall survival and an osteoblastic phenotype. Therefore, the function of HSP60 was investigated in more detail. Immunohistochemical analysis revealed heterogeneous staining for HSP60 in tumors. The highest...
Source: Cell Stress and Chaperones - March 6, 2013 Category: Cytology Authors: Selvarajah GT, Bonestroo FA, Kirpensteijn J, Kik MJ, van der Zee R, van Eden W, Timmermans-Sprang EP, Slob A, Mol JA Tags: Cell Stress Chaperones Source Type: research

SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells.
In this study, we assessed the antitumor activity of melatonin against human osteosarcoma cells (9607 cell line) and explored the role of SIRT1 in the activity of melatonin. melatonin treatment resulted in strong antitumor activity, as evidenced not only by reductions in tumor cell vitality, adhesion ability, migration ability and glutathione (GSH) levels but also by increases in the apoptotic index and reactive oxygen species. Additionally, melatonin treatment down-regulated SIRT1 and up-regulated acetylated-p53. Sirtinol (a known SIRT1 inhibitor) and SIRT1 siRNA further enhanced the antitumor activity of melatonin, while...
Source: European Journal of Pharmacology - May 29, 2013 Category: Drugs & Pharmacology Authors: Cheng Y, Cai L, Jiang P, Wang J, Gao C, Feng H, Wang C, Pan H, Yang Y Tags: Eur J Pharmacol Source Type: research